On October 7, AKESO fell 3.16% in regular trading, trading at HK$107.1, with Turnover of HK$84.48 million. The decline was driven by a broad-based pullback across the biotechnology sector, as investors locked in profits following several days of strong gains.
The Hang Seng Biotech Index fell 3.15%, the Hang Seng Healthcare Index dropped 2.73%, and the Wind Hong Kong China Innovative Drug Index slid 2.39%, exerting systematic pressure on individual names. Within the sector, GenScript Biotech plunged 14.81%, Zai Lab fell 4.47%, and AKESO followed the sector lower.
AKESO is an investment holding company focused on the research, development, manufacturing, and commercialization of affordable antibody drugs for global patients. Its pipeline spans oncology, autoimmune, and metabolic diseases, with key products including cadonilimab, ivonescimab, and penpulimab.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)